Pmv Pharmaceuticals Inc (PMVP) Stock Price, Quote & News

Company Profile

PMV Pharmaceuticals, Inc., a precision oncology company, engages in the discovery and development of small molecule and tumor-agnostic therapies for p53 mutations in cancer. It's lead product candidate is rezatapopt, an orally available small molecule that potently and selectively correct p53 misfolding caused by p53 mutation, Y220C, while sparing wild-type p53. The company was formerly known as PJ Pharmaceuticals, Inc. and changed its name to PMV Pharmaceuticals, Inc. in July 2013. PMV Pharmace...

Industry: Biotechnology

Sector: Healthcare

Phone: 609 642 6670

Website: www.pmvpharma.com

Address:

400 Alexander Park Drive, Suite 301, Princeton, United States

PaulLaurent Sep. 13 at 9:26 AM

🌀 Weekly Swing Trade Recap $ASST – +280% from our entry zone. Big winner; multiple scale-out points. $COCP – +169% from our entry zone. Trend held; great adds on strength. $PMVP – +48% from our entry zone. Solid follow-through; trims into spikes paid. $LWLG – Tagged the +10% profit zone, then dumped immediately; quick take-profit was key. $EDIT – Breakeven. No decisive push; preserved capital. XRTX – Breakeven. Low momentum; no reason to force it. Takeaways: 3 green, 1 quick tap-and-fade, 2 flat. Keep scaling into strength, move stops to breakeven after PT1, and stay ruthless about exits when momentum stalls.

1 · Reply

ThomasJerryLLC Sep. 12 at 4:26 PM

$PMVP pretty straightforward plan: continue Phase 2 enrollment worldwide with top line data expected in 2026. As long as there are no safety/efficacy issues that readout will be the next major catalyst. NDA submission in q1 2027 https://www.sec.gov/Archives/edgar/data/1699382/000119312525199857/d90438dex992.htm

0 · Reply

Mystic80 Sep. 11 at 1:38 PM

$PMVP I added to my position. Yesterday's pure manipulation. Company had good results on a high potential product. Why sell....? I just wait....yes, it's phase 2...but nda is inevitable.

1 · Reply

builderup Sep. 11 at 12:42 PM

Watchlist $PMVP $FFAI $SVRE $GPUS Let’s go!

0 · Reply

KryptonianTrader Sep. 11 at 10:11 AM

$PMVP

0 · Reply

YBC_oppa Sep. 11 at 2:56 AM

$PMVP Same chart pattern like $PALI back in 7 August 2025, a "good" PR, nothing significant like a late stage FDA trial approval, just some minor improvement in the trial, and bag holder rushed to exit Its a long way to go for pre-clinical biotech companies with no revenue as their research still need to go to phase 1-2-3 which would take 3-6 years if it even materialize to sell the product to market

0 · Reply

Ycapital Sep. 10 at 9:59 PM

$PMVP dumped because FDA likely requires a full Phase 3, meaning 2 more years + dilution risk despite $2.8/share in cash.

2 · Reply

KryptonianTrader Sep. 10 at 8:53 PM

$PMVP Overreaction and Shorts took advantage.. Watch

0 · Reply

WallStArb Sep. 10 at 6:51 PM

$PMVP there is no reason at any price to get back into this - it’s done for 9 - 12 months unless this trades at a liquidation valuation (30 -40m mkt cap) it’s not worth it

0 · Reply

SeannyHand Sep. 10 at 6:34 PM

$RBNE thank you again @PennySpot to find any good stock to trade ! This one was mucho good for today ! $FFAI $PMVP $CPOP $SPY only on this week I'm at +1200%

0 · Reply

Small-Cap PMV Pharmaceuticals Cancer Drug Shows Confirmed Responses In 8 Tumor Types

Sep 10, 2025, 7:00 AM EDT - 4 days ago

PMV Pharmaceuticals Announces Promising Rezatapopt Monotherapy Interim Data From PYNNACLE Phase 2 Trial Across Multiple Solid Tumors With a TP53 Y220C Mutation

Aug 7, 2025, 8:42 AM EDT - 5 weeks ago

PMV Pharmaceuticals Reports Second Quarter 2025 Financial Results and Corporate Highlights

May 23, 2025, 4:05 PM EDT - 4 months ago

PMV Pharmaceuticals to Participate at Upcoming Investor Conferences

Mar 3, 2025, 8:00 AM EST - 6 months ago

PMV Pharmaceuticals Reports Full Year 2024 Financial Results and Corporate Highlights

May 29, 2024, 7:00 AM EDT - 1 year ago

Foundation Medicine and PMV Pharma Announce Collaboration to Develop Companion Diagnostic for Rezatapopt, a First-In-Class, Investigational, Selective p53 Y220C Reactivator

May 9, 2024, 8:00 AM EDT - 1 year ago

PMV Pharmaceuticals Reports First Quarter 2024 Financial Results and Corporate Highlights

Mar 27, 2024, 8:00 AM EDT - 1 year ago

PMV Pharmaceuticals Announces First Patient Dosed in Global Tumor-Agnostic Phase 2 PYNNACLE Trial for Rezatapopt in TP53 Y220C-Positive Solid Tumors

Mar 18, 2024, 4:01 PM EDT - 1 year ago

PMV Pharmaceuticals PYNNACLE Phase I Data of Rezatapopt in Advanced Ovarian Cancer Featured in Late-Breaking Oral Presentation at 2024 SGO Annual Meeting on Women's Cancer

Feb 29, 2024, 4:01 PM EST - 1 year ago

PMV Pharmaceuticals Reports Full Year 2023 Financial Results and Corporate Highlights

Jan 18, 2024, 4:01 PM EST - 1 year ago

PMV Pharmaceuticals Announces Prioritization of PC14586 Clinical Development and Extended Cash Runway

Jan 5, 2024, 4:01 PM EST - 1 year ago

PMV Pharmaceuticals Strengthens Leadership with Key Appointments as Company Advances into Late-Stage Development

Nov 14, 2023, 6:50 PM EST - 1 year ago

PMV Pharmaceuticals: In A Stronger Position Now Than Before, At A Lower Price

Nov 9, 2023, 8:00 AM EST - 2 years ago

PMV Pharmaceuticals Reports Third Quarter 2023 Financial Results and Corporate Highlights

Oct 12, 2023, 12:30 PM EDT - 2 years ago

PMV Pharmaceuticals Updated PC14586 Phase 1 Data Demonstrated Anti-Tumor Activity Across Multiple Solid Tumor Types With a TP53 Y220C Mutation

Oct 11, 2023, 12:00 PM EDT - 2 years ago

PMV Pharmaceuticals to Present Updated Phase 1 Data on PC14586 at the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics and Host a KOL Webinar

Sep 20, 2023, 4:05 PM EDT - 2 years ago

PMV Pharmaceuticals to Present Updated Phase 1 Data on PC14586 at the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Aug 30, 2023, 9:20 AM EDT - 2 years ago

PMV Pharmaceuticals: A 5-Month Run-Up Is Justified

Aug 9, 2023, 8:00 AM EDT - 2 years ago

PMV Pharmaceuticals Reports Second Quarter 2023 Financial Results and Corporate Highlights

Jun 6, 2023, 4:01 PM EDT - 2 years ago

PMV Pharmaceuticals to Participate in the Goldman Sachs Global Healthcare Conference

May 10, 2023, 8:00 AM EDT - 2 years ago

PMV Pharmaceuticals Reports First Quarter 2023 Financial Results and Corporate Highlights

Mar 1, 2023, 8:00 AM EST - 2 years ago

PMV Pharmaceuticals Reports Full Year 2022 Financial Results and Corporate Highlights

Feb 28, 2023, 4:05 PM EST - 2 years ago

PMV Pharmaceuticals to Participate at Upcoming Investor Conferences in March

Nov 22, 2022, 8:00 AM EST - 3 years ago

PMV Pharmaceuticals to Participate in the 5th Annual Evercore ISI HealthCONx Conference

Nov 8, 2022, 8:00 AM EST - 3 years ago

PMV Pharmaceuticals Reports Third Quarter 2022 Financial Results and Corporate Highlights

Nov 4, 2022, 8:00 AM EDT - 3 years ago

PMV Pharmaceuticals Appoints Industry Veteran Dr. Carol Gallagher to Board of Directors

Aug 9, 2022, 8:00 AM EDT - 3 years ago

PMV Pharmaceuticals Reports Second Quarter 2022 Financial Results and Corporate Highlights

Jul 18, 2022, 8:00 AM EDT - 3 years ago

PMV Pharmaceuticals Announces a Clinical Trial Collaboration with Merck to Evaluate PC14586 in Combination with KEYTRUDA® (pembrolizumab) in Patients with Advanced Solid Tumors

Jun 7, 2022, 12:00 PM EDT - 3 years ago

PMV Pharmaceuticals Initial PC14586 Phase 1 Data Presented at ASCO Demonstrated Anti-Tumor Activity Across Multiple Solid Tumor Types With a p53 Y220C Mutation

May 26, 2022, 5:05 PM EDT - 3 years ago

PMV Pharmaceuticals Announces Initial PC14586 Phase 1 Clinical Data to be Presented at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting

May 10, 2022, 7:30 AM EDT - 3 years ago

PMV Pharmaceuticals Reports First Quarter 2022 Financial Results and Corporate Highlights

Apr 27, 2022, 10:30 AM EDT - 3 years ago

PMV Pharmaceuticals to Present PC14586 Phase 1 Clinical Data at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting

Mar 1, 2022, 7:15 AM EST - 3 years ago

PMV Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results and Corporate Highlights

Feb 28, 2022, 8:00 AM EST - 3 years ago

PMV Pharmaceuticals to Participate in the 42nd Annual Cowen Health Care Conference

Feb 3, 2022, 8:00 AM EST - 3 years ago

PMV Pharmaceuticals to Participate in the Guggenheim Healthcare Talks 2022 Oncology Day

Jan 6, 2022, 8:00 AM EST - 4 years ago

PMV Pharma Announces Changes to its Board of Directors

Nov 22, 2021, 8:00 AM EST - 4 years ago

PMV Pharma to Present at the Evercore ISI 4th Annual HealthCONx Conference

Nov 12, 2021, 7:15 AM EST - 4 years ago

PMV Pharmaceuticals Reports Third Quarter 2021 Financial Results and Corporate Highlights

Sep 2, 2021, 8:00 AM EDT - 4 years ago

PMV Pharmaceuticals to Present at the Morgan Stanley 19th Annual Global Healthcare Conference

Aug 13, 2021, 8:00 AM EDT - 4 years ago

PMV Pharmaceuticals Reports Second Quarter 2021 Financial Results and Corporate Highlights

Jun 9, 2021, 8:00 AM EDT - 4 years ago

PMV Pharmaceuticals Announces Participation at the Bank of America Securities 2021 Napa Biopharma Virtual Conference

May 14, 2021, 8:00 AM EDT - 4 years ago

PMV Pharmaceuticals Reports First Quarter 2021 Financial Results and Corporate Highlights

May 5, 2021, 8:00 AM EDT - 4 years ago

PMV Pharmaceuticals Announces Participation at the Bank of America Healthcare Conference

Apr 10, 2021, 1:31 PM EDT - 4 years ago

PMV Pharma Presents Late-Breaking Preclinical Data on Lead Product Candidate PC14586 at the American Association for Cancer Research Annual Meeting 2021

Apr 6, 2021, 8:00 AM EDT - 4 years ago

PMV Pharma Strengthens Board of Directors with Appointment of Dr. Charles Baum

Mar 10, 2021, 4:31 PM EST - 4 years ago

PMV Pharmaceuticals Announces Presentation of PC14586 Preclinical Data at the American Association for Cancer Research (AACR) Annual Meeting 2021

Mar 3, 2021, 4:01 PM EST - 4 years ago

PMV Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results and Corporate Highlights

Feb 16, 2021, 8:00 AM EST - 4 years ago

PMV Pharma Appoints p53 Pioneer Dr. Guillermina Lozano to Scientific Advisory Board

Nov 24, 2020, 5:00 PM EST - 5 years ago

PMV Pharmaceuticals to Present at Evercore ISI 3rd Annual HealthCONx Conference

Nov 23, 2020, 8:00 AM EST - 5 years ago

PMV Pharma Doses First Patient in Phase 1/2 Study of PC14586, a First-in-Class Precision Oncology Therapy That Targets Mutant p53

PaulLaurent Sep. 13 at 9:26 AM

1 · Reply

ThomasJerryLLC Sep. 12 at 4:26 PM

0 · Reply

Mystic80 Sep. 11 at 1:38 PM

$PMVP I added to my position. Yesterday's pure manipulation. Company had good results on a high potential product. Why sell....? I just wait....yes, it's phase 2...but nda is inevitable.

1 · Reply

builderup Sep. 11 at 12:42 PM

Watchlist $PMVP $FFAI $SVRE $GPUS Let’s go!

0 · Reply

KryptonianTrader Sep. 11 at 10:11 AM

$PMVP

0 · Reply

YBC_oppa Sep. 11 at 2:56 AM

0 · Reply

Ycapital Sep. 10 at 9:59 PM

$PMVP dumped because FDA likely requires a full Phase 3, meaning 2 more years + dilution risk despite $2.8/share in cash.

2 · Reply

KryptonianTrader Sep. 10 at 8:53 PM

$PMVP Overreaction and Shorts took advantage.. Watch

0 · Reply

WallStArb Sep. 10 at 6:51 PM

$PMVP there is no reason at any price to get back into this - it’s done for 9 - 12 months unless this trades at a liquidation valuation (30 -40m mkt cap) it’s not worth it

0 · Reply

SeannyHand Sep. 10 at 6:34 PM

$RBNE thank you again @PennySpot to find any good stock to trade ! This one was mucho good for today ! $FFAI $PMVP $CPOP $SPY only on this week I'm at +1200%

0 · Reply

MadHatterTrades74 Sep. 10 at 6:08 PM

$PMVP this suppression has me thinking an offering is coming in after hours. yes they are liquid but no more catalysts until 2026 mean this is their last great chance to get investors onboard. • Once the S-3 is effective, management can launch an offering without pre-announcing — they simply drop a 424B5 prospectus supplement the same day they price the deal. So yes, an offering could technically hit after hours today without any forewarning. 2. How This Connects to Today’s Price Action The combination of factors you’re seeing is textbook “pre-offering suppression” behavior: • Good PR (trial data) → triggers volume surge and initial pop. • Aggressive ask walls cap the breakout → we saw 139K @ $1.28 get absorbed. • After the wall gets eaten, algorithmic selling kicks in • Price is walked down 10–20% intraday → makes any offering look “discounted” to institutions buying the new shares. This is a well-known tactic among small-cap biotech underwriters and their syndicate desks.

1 · Reply

Jabed206 Sep. 10 at 5:14 PM

$PMVP data not stand out

0 · Reply

merlin8121 Sep. 10 at 5:13 PM

$PMVP incredible chatgpt :) 1️⃣ Drug specificity Rezatapopt is specifically designed to stabilize the mutant p53 protein Y220C, restoring its normal function. No other approved drug acts so directly on this mutation. 2️⃣ Observed efficacy Overall ORR ~32–33%, but in ovarian tumors with Y220C it reaches up to 47%. Median duration of response: 6–7 months, promising compared to other non-targeted options (immunotherapy or off-label chemo). 3️⃣ Safety profile Adverse events are mild to moderate, with few cases of treatment discontinuation. Better tolerability compared to many traditional chemotherapy regimens. 4️⃣ Competitive context Other drugs in the sector do not reach such high ORR specifically in TP53 Y220C. Therefore, Rezatapopt represents the ideal precision therapy when the biomarker is

0 · Reply

Alice_in_Dollarland Sep. 10 at 5:02 PM

$PMVP You can quote me. I think this will go up within the next 2-3 weeks.

1 · Reply

WallStArb Sep. 10 at 4:53 PM

$PMVP the results were mediocre and if they push on it will be a waste of $ and resources - they need cash or a partner now - all catalysts going forward are negative for 18 months

0 · Reply

WallStArb Sep. 10 at 4:51 PM

$PMVP I am surprised this is < $1

0 · Reply

Tabinvest Sep. 10 at 4:43 PM

$PMVP strengthen your plays by only trading less than 10-20m float this will put the odds more in our favor imo

0 · Reply

Alice_in_Dollarland Sep. 10 at 4:40 PM

$PMVP maybe, but was commenting after looking over the # of shares borrowed.

0 · Reply

WeThePeople102 Sep. 10 at 4:32 PM

$PMVP this is fucking wild, from up 60% to down 20% in few hours

0 · Reply

Tabinvest Sep. 10 at 4:31 PM

$PMVP If it were just shorts, you’d usually get a squeeze bounce or at least one intraday flip before fade. The fact that it went straight down suggests major holders or funds were unloading into liquidity. imo

1 · Reply

VixMania Sep. 10 at 4:09 PM

$PMVP GARBAGE

0 · Reply

Alice_in_Dollarland Sep. 10 at 4:05 PM

$PMVP Shorts not done yet, but sounds like a STEAL.

0 · Reply

Market Cap	65.18M
Revenue (ttm)	0.00
Net Income (ttm)	-58.71M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	1,688,900
Avg Vol	1,197,906
Day's Range	N/A - N/A
Shares Out	52.99M
Stochastic %K	6%
Beta	1.52
Analysts	Strong Sell
Price Target	$5.80